Response to methotrexate in a chronic inflammatory demyelinating polyradiculoneuropathy patient

Muscle and Nerve

Volumn 39, Issue 3, 2009, Pages 386-388

  Díaz Manera, Jordi ^a,b   Rojas García, Ricard ^a,b   Gallardo, Eduard ^a,b   Illa, Isabel ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Chronic inflammatory demyelinating polyradiculoneuropathy; Intravenous inmunoglobulins; Methotrexate; Steroids; Treatment

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; CASE REPORT; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MALE; NAUSEA; POLYRADICULONEUROPATHY; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; WHEELCHAIR;

DISABILITY EVALUATION; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; NEURAL CONDUCTION; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; TREATMENT OUTCOME;

EID: 62849094959     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.21171     Document Type: Article

References (9)

1. Fialho D, Chan YC, Allen DC, Reilly MM, Hughes RA. Treatment of chronic inflammatory demyelinating polyradiculoneuropathy with methotrexate. J Neurol Neurosurg Psychiatry 2006;77:544-547.
2. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195-201.
3. Hughes RA, Bouche P, Cornblath DR, Evers E, Hadden RD, Hahn A, et al. European Federation of Neurological Societies/ Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. Eur J Neurol 2006;13:326-332.
4. Hughes RA, Swan AV, van Doorn PA. Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev (2003) CD003280.
5. Koller H, Kieseier BC, Jander S, Hartung HP Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005;352: 1343-1356.
6. Merkies I, Schmitz P, Van der Meché F, Samijn J, Van Doorn P. Psychometric evaluation of a new handicap scale in immune-mediated polyneuropathies. Muscle Nerve 2002;26:370-377
7. Rankin L. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J 1957;2:200-215.
8. Ryan MM, Grattan-Smith PJ, Procopis PG, Morgan G, Ouvrier RA. Childhood chronic inflammatory demyelinating polyneuropathy: clinical course and long-term outcome. Neuromuscul Disord 2000;10:398-406.
9. Saperstein DS, Katz JS, Amato AA, Barohn RJ. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-324.